DeCure for Salivary gland adenoid cystic carcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for salivary gland adenoid cystic carcinoma — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSalivary gland adenoid cystic carcinoma maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for salivary gland adenoid cystic carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysine demethylase 6A (KDM6A) — KDM6A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet e7zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FUL · 1.649 Å · ligand 1-methyl-5-oxidanyl-4-oxidanylidene-pyridine-2-carboxylic acid (E7Z). Experimental structure, not a prediction.
What the evidence adds up to
A 1996 review of chemotherapy for metastatic adenoid cystic carcinoma of salivary glands found no single drug or combination that could be regarded as a treatment of choice. Among four unpublished cases given cyclophosphamide, one patient responded and another obtained pain relief. The authors concluded that systematic, multi-institutional studies were needed to determine appropriate systemic treatment.
A 2017 case report described a 50‑year‑old woman with a minor salivary gland adenoid cystic carcinoma of the hard palate that was identified incidentally. After surgical treatment, no recurrence was noted at ten years of follow‑up. The report emphasised that adenoid cystic carcinoma is a slow‑growing but aggressive neoplasm with a tendency for late recurrence, and that the surgeon’s clinical judgement should guide treatment.
A 2014 review of signalling pathways stated that invasion and metastasis of salivary gland adenoid cystic carcinoma involve multiple signalling pathways and complex mechanisms, but it did not report any clinical data or therapeutic interventions.
The evidence base remains limited. No randomised trial has established a standard systemic therapy for metastatic disease. The single‑agent cyclophosphamide data from 1996 are sparse and decades old. What is missing is a properly funded, multi‑institutional trial that stratifies patients by tumour stage, histological subtype and molecular profile, and that tests prospectively defined drug regimens.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer Control · 1996 · 35 citations
Metastatic Adenoid Cystic Carcinoma of Salivary Glands: Case Reports and Review of the Literature
AbstractBACKGROUND: Adenoid cystic carcinoma is an uncommon tumor of the salivary gland. Little has been published on the chemotherapy of this neoplasm. METHODS: The literature on this disease is reviewed, and data from seven unpublished cases are presented. RESULTS: Four patients received cyclophosphamide. One responded, and another had pain relief. The literature review did not identify any single drug or combination that might be regarded as the treatment of choice. CONCLUSIONS: Systematic, multi-institutional studies are required to determine appropriate systemic treatment for metastatic adenoid cystic carcinoma of salivary gland origin.
Journal of Dental Health Oral Disorders and Therapy · 2017 · 0 citations · open access
Coincidentally Identified Case of Minor Salivary Gland Adenoid Cystic Carcinoma
AbstractMinor salivary gland tumors of the oral cavity are rare. They represent approximately 29% of all minr salivary gland tumors and the most common intraoral site is hard palate. It is a slow growing but aggressive neoplasm with a tendency for recurrence. In this study we will present a 50 years old female patient who was presented with a mass localized at the right portion of the hard palate and was diagnosed incidentally with Adenoid Cystic Carcinoma. In the follow up, no recurrence was noted 10 years after the surgical treatment. Adenoid cystic carcinoma is a salivary gland malignancy with unexpected growth and late recurrence. Our aim was to review the treatment choices of the Adenoid Cystic Carcinoma under the light of current data and to express the importance of surgeon's clinical opinion upon the treatment to be applied.
Research progress of signaling pathways mediating the proliferation, invasion and metastasis of salivary gland adenoid cystic carcinoma
AbstractSalivary gland adenoid cystic carcinoma is one of the most common malignant salivary gland tumors.Its invasion and metastasis are multi-stage and multifactorial processes,in which complex mechanisms and multiple signaling pathways are involved.Here,this article reviews the research progress in signaling pathways of salivary gland adenoid cystic carcinoma.
Key words:
Salivary adenoid cystic carcinoma; Signal path; Cell factor
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
